196 related articles for article (PubMed ID: 32497121)
1. dBMHCC: A comprehensive hepatocellular carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers.
Chu YW; Chien CH; Sung MI; Chen CW; Chen YT
PLoS One; 2020; 15(6):e0234084. PubMed ID: 32497121
[TBL] [Abstract][Full Text] [Related]
2. dbPHCC: a database of prognostic biomarkers for hepatocellular carcinoma that provides online prognostic modeling.
Ouyang J; Sun Y; Li W; Zhang W; Wang D; Liu X; Lin Y; Lian B; Xie L
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2688-95. PubMed ID: 26940364
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics Analysis Identifies Protein Tyrosine Kinase 7 (PTK7) as a Potential Prognostic and Therapeutic Biomarker in Stages I to IV Hepatocellular Carcinoma.
Zou RC; Liang Y; Li LL; Tang JZ; Yang YP; Geng YC; He J; Luo LY; Li WX; Sun ZW; Yuan HL
Med Sci Monit; 2019 Nov; 25():8618-8627. PubMed ID: 31730575
[TBL] [Abstract][Full Text] [Related]
5. Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis.
Liu XN; Cui DN; Li YF; Liu YH; Liu G; Liu L
World J Gastroenterol; 2019 Aug; 25(30):4199-4212. PubMed ID: 31435173
[TBL] [Abstract][Full Text] [Related]
6. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.
Ren FH; Yang H; He RQ; Lu JN; Lin XG; Liang HW; Dang YW; Feng ZB; Chen G; Luo DZ
BMC Cancer; 2018 Jan; 18(1):12. PubMed ID: 29298665
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel blood-based HCC-specific diagnostic biomarkers for human hepatocellular carcinoma.
Yin L; He N; Chen C; Zhang N; Lin Y; Xia Q
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1908-1916. PubMed ID: 31072138
[TBL] [Abstract][Full Text] [Related]
8. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.
Song PP; Xia JF; Inagaki Y; Hasegawa K; Sakamoto Y; Kokudo N; Tang W
World J Gastroenterol; 2016 Jan; 22(1):262-74. PubMed ID: 26755875
[TBL] [Abstract][Full Text] [Related]
9. Dynamic edge-based biomarker non-invasively predicts hepatocellular carcinoma with hepatitis B virus infection for individual patients based on blood testing.
Lu Y; Fang Z; Li M; Chen Q; Zeng T; Lu L; Chen Q; Zhang H; Zhou Q; Sun Y; Xue X; Hu Y; Chen L; Su S
J Mol Cell Biol; 2019 Aug; 11(8):665-677. PubMed ID: 30925583
[TBL] [Abstract][Full Text] [Related]
10. Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker.
Li C; Zhou D; Jiang X; Liu M; Tang H; Mei Z
Gene; 2019 May; 698():9-18. PubMed ID: 30825595
[TBL] [Abstract][Full Text] [Related]
11. Identifying prognostic features by bottom-up approach and correlating to drug repositioning.
Li W; Yu J; Lian B; Sun H; Li J; Zhang M; Li L; Li Y; Liu Q; Xie L
PLoS One; 2015; 10(3):e0118672. PubMed ID: 25738841
[TBL] [Abstract][Full Text] [Related]
12. Hypo-phosphorylated CD147 promotes migration and invasion of hepatocellular carcinoma cells and predicts a poor prognosis.
Jin J; Wang SJ; Cui J; Li L; Li JY; Liu FL; Sun XX; Jiang JL; Cui HY; Chen ZN
Cell Oncol (Dordr); 2019 Aug; 42(4):537-554. PubMed ID: 31016558
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis and translational perspective of hepatocellular carcinoma: Identification of diagnostic protein biomarkers by an onco-proteogenomics approach.
Chiou SH; Lee KT
Kaohsiung J Med Sci; 2016 Nov; 32(11):535-544. PubMed ID: 27847095
[TBL] [Abstract][Full Text] [Related]
14. Identification of diagnostic long non‑coding RNA biomarkers in patients with hepatocellular carcinoma.
Li G; Shi H; Wang X; Wang B; Qu Q; Geng H; Sun H
Mol Med Rep; 2019 Aug; 20(2):1121-1130. PubMed ID: 31173205
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis.
He S; Zhang DC; Wei C
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):426-34. PubMed ID: 25746139
[TBL] [Abstract][Full Text] [Related]
16. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics.
Masuda T; Miyoshi E
Clin Chem Lab Med; 2011 Jun; 49(6):959-66. PubMed ID: 21428856
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma.
Lin P; Wen DY; Dang YW; He Y; Yang H; Chen G
Cell Physiol Biochem; 2018; 47(3):925-947. PubMed ID: 29843122
[TBL] [Abstract][Full Text] [Related]
18. Novel molecular targets for diagnosis and treatment of hepatocellular carcinoma.
Ma L; Ji L; Yu Y; Wang J
Discov Med; 2015 Jan; 19(102):7-14. PubMed ID: 25636956
[TBL] [Abstract][Full Text] [Related]
19. Low DMT1 Expression Associates With Increased Oxidative Phosphorylation and Early Recurrence in Hepatocellular Carcinoma.
Hoki T; Katsuta E; Yan L; Takabe K; Ito F
J Surg Res; 2019 Feb; 234():343-352. PubMed ID: 30527495
[TBL] [Abstract][Full Text] [Related]
20. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.
Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
